In this issue:
OPAL Balance provides long-term safety and efficacy data for tofacitinib
Methotrexate discontinuation possible in tofacitinib-treated patients
Upadacitinib for PsA refractory to biologics
Brodalumab improves both joint- and skin-related symptoms
SPIRIT confirms the superiority of ixekizumab over adalimumab in biological-naïve patients
The efficacy of ixekizumab is independent of concomitant methotrexate use
The impact of smoking on prevalence of psoriasis and PsA
Comorbidities impact on disease activity, patient global assessment and function
Inferior outcomes in patients with both skin and joint involvement
Composite Measures of Disease Activity in PsA
Please login below to download this issue (PDF)